argenx Clinical Trial Pipeline — 33 Active Studies

argenx pipeline at a glance (March 2026)

About the argenx clinical program

argenx has built one of the most productive clinical platforms in autoimmune disease through its ABDEG technology — engineered antibodies that enhance FcRn-mediated IgG catabolism, reducing pathogenic autoantibody levels. Efgartigimod (Vyvgart, Vyvdura) is the lead asset: a first-in-class FcRn antagonist approved in generalized myasthenia gravis (gMG), primary immune thrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and pemphigus vulgaris. Efgartigimod's mechanism — reducing all IgG subclasses including pathogenic autoantibodies — positions it as a platform therapy across any antibody-mediated autoimmune disease. argenx is systematically expanding efgartigimod into additional indications including thyroid eye disease, Sjögren's disease, multifocal motor neuropathy (MMN), spinal muscular atrophy (SMA), and Lambert-Eaton myasthenic syndrome (LEMS). Empasiprubart (ARGX-117), targeting complement C2, represents the company's second platform — entering Phase 3 in MMN and other complement-mediated diseases.

Key therapeutic areas

• Neuromuscular disease (myasthenia gravis, CIDP, MMN, LEMS)
• Autoimmune disease (ITP, pemphigus, thyroid eye disease, Sjögren's)
• FcRn-mediated IgG reduction (efgartigimod platform)
• Complement inhibition (empasiprubart, C2 targeting)
• Rare pediatric diseases (SMA, congenital myasthenic syndrome)
• Neonatal medicine (antibody-mediated neonatal disease)

Key pipeline programs

• Efgartigimod (Vyvgart IV / Vyvdura SC) — FcRn antagonist, gMG/ITP/CIDP/pemphigus
• Efgartigimod subcutaneous — next-gen delivery, multiple indications
• Empasiprubart (ARGX-117) — anti-C2 complement inhibitor, MMN and others
• ARGX-119 — anti-C2, neuromuscular (earlier-stage)
• ARGX-118 — IgE-FcRn modulator (allergic disease)
• ARGX-220 — antibody-mediated rejection

Top argenx trial indications

Condition / Indication	Trials
["Primary Immune Thrombocytopenia"]	2
["Thyroid Eye Disease"]	2
["Generalized Myasthenia Gravis"]	2
["Primary Sjogrens Disease"]	1
["Multifocal Motor Neuropathy"]	1
["Antibody-mediated Rejection"]	1
["Delayed Graft Function"]	1
["Spinal Muscular Atrophy (SMA)"]	1

Why monitor argenx's clinical trial activity

argenx is registering new efgartigimod trials across autoimmune conditions on a near-monthly basis — each new indication registration represents a potential $1B+ market opportunity. Their trial data in CIDP (which showed unprecedented response rates) has set the bar for future FcRn inhibitor approvals. Competitors (UCB's rozanolixizumab, Johnson & Johnson's nipocalimab) are tracking argenx's trial expansions closely.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to argenx's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks argenx trials

• Sponsor normalization: argenx may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is efgartigimod and how does it work?

Efgartigimod (Vyvgart/Vyvdura) is a human IgG1 antibody Fc fragment engineered via argenx's ABDEG technology to bind FcRn (neonatal Fc receptor) with high affinity at physiological pH. FcRn normally recycles IgG antibodies back into circulation; by blocking FcRn, efgartigimod accelerates degradation of all IgG subclasses — including the pathogenic autoantibodies that drive myasthenia gravis, ITP, and other antibody-mediated autoimmune diseases. Because the mechanism targets all IgGs non-selectively, it works regardless of the specific autoantibody involved, making it a broad platform across antibody-mediated diseases.

How many argenx trials are currently recruiting?

Based on current ClinicalTrials.gov data, 19 argenx-sponsored trials are actively recruiting. argenx runs one of the most active Phase 3 programs in rare autoimmune disease — monitoring their trial registrations provides early warning of new indication entries before analyst coverage.

Can DataLookout alert me to new argenx indication expansions?

Yes. DataLookout monitors ClinicalTrials.gov daily for all argenx-registered trial activity. Set a watchlist for argenx to receive alerts when new indications are registered, when Phase 2/3 trials open for enrollment, or when existing trial protocols are amended. This is particularly valuable for tracking empasiprubart (complement C2) as it moves into new indications.